A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the Dose-Response Profile of A-101 Topical Solution in Subjects With Seborrheic Keratosis of the Face

Trial Profile

A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the Dose-Response Profile of A-101 Topical Solution in Subjects With Seborrheic Keratosis of the Face

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Mar 2015

At a glance

  • Drugs Hydrogen peroxide (Primary)
  • Indications Seborrhoeic keratosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Aclaris Therapeutics
  • Most Recent Events

    • 17 Mar 2015 Status changed from active, no longer recruiting to completed, based on the results published in Aclaris Therapeutics media release.
    • 17 Mar 2015 Primary endpoint (Physicians Lesion Assessment (PLA) Score) has been met, according to Aclaris Therapeutics media release.
    • 17 Mar 2015 Results published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top